Sugi Predict

Sugi Predict / Compounds / SCHEMBL2233431

SCHEMBL2233431

SCHEMBL2233431

O=C(NC[C@H](O)CNc1ccc(N2CCOCC2=O)cc1)c1ccc(Cl)s1

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 18/20 0.67
▸ ABCB11 O95342 1/20 0.65
▸ F2 P00734 1/20 0.65
▸ ST14 Q9Y5Y6 1/20 0.65
▸ PTGS2 P35354 1/20 0.57
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ CYP2J2 P51589 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276611 1.00 F10 (0.67) F10ABCB11F2ST14PTGS2
SCHEMBL78971 1.00 F10 (0.67) F10ABCB11F2ST14PTGS2
SCHEMBL14838626 0.90 F10 (0.67) F10ABCB11F2ST14PTGS2
SCHEMBL10001459 0.89 F10 (0.65) F10ABCB11F2ST14PTGS2
SCHEMBL25518142 0.88 F10 (0.55) F10ABCB11F2ST14PTGS2
SCHEMBL78973 0.88 F10 (0.62) F10ABCB11F2ST14
SCHEMBL2995671 0.88 F10 (0.59) F10ABCB11F2ST14CYP3A4
SCHEMBL2995676 0.88 F10 (0.59) F10ABCB11F2ST14CYP3A4
SCHEMBL78814 0.87 F10 (0.62) F10ABCB11F2ST14
SCHEMBL77157 0.86 F10 (0.50) F10ABCB11F2ST14PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150218145-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN RANBAXY LABORATORIES LIMITED (IN) 2015-08-06 — — US claimed
EP-2900663-A2 PROCESS FOR THE PREPARATION OF RIVAROXABAN Ranbaxy Laboratories Limited (IN) 2015-08-05 — — EP claimed
WO-2015011617-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN RANBAXY LABORATORIES LIMITED (IN) 2015-01-29 — — WO claimed
US-20100081807-A1 METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE BAYER HEALTHCARE AG (DE) 2010-04-01 — — US claimed
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide BAYER HEALTHCARE AG (DE) 2007-06-28 — — US claimed
EP-2705028-B1 PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2019-08-21 — — EP disclosed
US-20170267669-A1 Process for the Preparation of Rivaroxaban CIPLA LIMITED (IN) 2017-09-21 — — US disclosed
US-9598403-B2 Process for the preparation of rivaroxaban AMNEAL PHARMACEUTICALS LLC (US) 2017-03-21 — — US disclosed
US-9556163-B2 Process for the preparation of a rivaroxaban and intermediates formed in said process EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2017-01-31 — — US disclosed
EP-2837628-B1 METHOD FOR PREPARING RIVAROXABAN INTERMEDIATE CHINA NAT MEDICINES GUORUI PHARMACEUTICAL CO LTD (CN) 2016-11-30 — — EP disclosed
EP-2895176-B1 RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF WANBURY LTD (IN) 2016-10-19 — — EP disclosed
US-9394292-B2 Rivaroxaban intermediate and preparation thereof WANBURY LTD. (IN) 2016-07-19 — — US disclosed
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide BAYER HEALTHCARE AG (DE) 2007-06-28 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
US-20070066615-A1 Heterocyclic compounds BAYER HEATHCARE AG (DE) 2007-03-22 — — US disclosed
WO-2006111285-A2 IMINO-OXAZOLIDINES AND USE THEREOF AS ANTICOAGULANTS BAYER HEALTHCARE AG (DE) 2006-10-26 — — WO disclosed
EP-1626969-A1 HETEROCYCLIC COMPOUNDS Bayer HealthCare AG (DE) 2006-02-22 — — EP disclosed
WO-2004101557-A1 HETEROCYCLIC COMPOUNDS BAYER HEALTHCARE AG (DE) 2004-11-25 — — WO disclosed
WO-2004060887-A1 METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE BAYER HEALTHCARE AG (DE) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149522-A1 Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide NT5C, NOX5, MT-ND5 F10 4544/4885ABCB11 4723/4885F2 3487/4885
US-20100081807-A1 METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE CBR3, NT5C, CBR1 F10 4090/4885ABCB11 3327/4885F2 3094/4885
US-20170267669-A1 Process for the Preparation of Rivaroxaban F7, F5, F2 F10 10/4885ABCB11 2630/4885F2 3/4885
US-20070066615-A1 Heterocyclic compounds F2, SERPINC1, TFPI F10 12/4885ABCB11 784/4885F2 1/4885
US-20150218145-A1 PROCESS FOR THE PREPARATION OF RIVAROXABAN VKORC1L1, PROC, VKORC1 F10 13/4885ABCB11 3848/4885F2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.